Pfizer Deals With Incyte, NicOx Reflect Emphasis On External Partnerships
Executive Summary
Pfizer appears to be closing out the year with a stepped-up emphasis on external partnerships through recent deals with Incyte and NicOx
You may also be interested in...
Big Pharma More Comfortable Giving Acquired Firms Independence
Big pharma appears increasingly comfortable giving acquired companies operational independence
Big Pharma More Comfortable Giving Acquired Firms Independence
Big pharma appears increasingly comfortable giving acquired companies operational independence
OSI Takes Wait-And-See Approach To Lucentis Impact On Macugen
An early 2006 launch of Genentech's wet age-related macular degeneration candidate Lucentis could impact sales of OSI/Eyetech's competing therapy, Macugen, by an estimated $75 mil. that year, OSI said